Investigation of the effects of ketoconazole on the pharmacokinetics of macitentan, a novel dual endothelin receptor antagonist, in healthy subjects

Clinical Pharmacokinetics

Volumn 52, Issue 8, 2013, Pages 685-692

  Atsmon, Jacob ^a,b   Dingemanse, Jasper ^c   Shaikevich, Dimitri ^a,b   Volokhov, Inna ^a,b   Sidharta, Patricia N ^c  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c ACTELION PHARMACEUTICALS LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACT 132577; DRUG METABOLITE; KETOCONAZOLE; MACITENTAN; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; ANTIFUNGAL AGENTS; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; HUMANS; KETOCONAZOLE; MALE; PYRIMIDINES; RECEPTOR, ENDOTHELIN A; RECEPTOR, ENDOTHELIN B; SULFONAMIDES; YOUNG ADULT;

EID: 84880807894     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-013-0063-8     Document Type: Article

References (31)

1. Kedzierski RM, Yanagisawa M. Endothelin system: the double-edged sword in health and disease. Annu Rev Pharmacol Toxicol. 2001;41:851-76.
2. Barton M, Yanagisawa M. Endothelin: 20 years from discovery to therapy. Can J Physiol Pharmacol. 2008;86(8):485-98.
3. Bolli MH, Boss C, Binkert C, et al. The discovery of N-[5-(4-bromophenyl) -6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N′- propylsulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonist. J Med Chem. 2012;55(17):7849-61.
4. Raja SG. Macitentan, a tissue-targeting endothelin receptor antagonist for the potential oral treatment of pulmonary arterial hypertension and idiopathic pulmonary fibrosis. Curr Opin Investig Drugs. 2010;11(9):1066-73.
5. Rubin L, Pulido T, Channick R. Effect of macitentan on morbidity and mortality in pulmonary arterial hypertension (PAH): Results from the SERAPHIN trial (Abstract). Chest. 2012;142:1026A.
6. Kummer O, Haschke M, Hammann F, et al. Comparison of the dissolution and pharmacokinetic profiles of two galenical formulations of the endothelin receptor antagonist macitentan. Eur J Pharm Sci. 2009;38(4):384-8.
7. Iglarz M, Binkert C, Morrison K, et al. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. J Pharmacol Exp Ther. 2008;327(3):736-45.
8. Weiss J, Theile D, Ruppell MA, et al. Interaction profile of macitentan, a new non-selective endothelin-1 receptor antagonist, in vitro. Eur J Pharmacol. 2013;701(1-3):168-75.
9. Gatfield J, Mueller Grandjean C, Sasse T, et al. Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells. PLoS One. 2012;7(10):e47662.
10. Sidharta PN, van Giersbergen PL, Halabi A, et al. Macitentan: entry-into-humans study with a new endothelin receptor antagonist. Eur J Clin Pharmacol. 2011;67(10):977-84.
11. Bruderer S, Aanismaa P, Homery MC, et al. Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist. AAPS J. 2012;14(1):68-78.
12. Sidharta PN, van Giersbergen PL, Wolzt M, et al. Lack of clinically relevant pharmacokinetic interactions between the dual endothelin receptor antagonist macitentan and sildenafil in healthy subjects. Am J Respir Crit Care Med. 2012;185:A4802.
13. Bruderer S, Hopfgartner G, Seiberling M, et al. Absorption, distribution, metabolism, and excretion of macitentan, a dual endothelin receptor antagonist, in humans. Xenobiotica. 2012;42(9):901-10.
14. Sidharta P, Lindegger N, van Giersbergen P, et al. Single-dose pharmacokinetics, safety, and tolerability of macitentan, a new dual endothelin receptor antagonist, in subjects with mild, moderate, or severe hepatic impairment. (Abstract). Chest. 2012;142:826A.
15. Sidharta P, Lindegger N, Ulč I, et al. Single-dose pharmacokinetics, safety, and tolerability of macitentan, a new dual endothelin receptor antagonist, in subjects with severe renal function impairment. (Abstract). Chest. 2012;142:830A.
16. FDA. Guidance for industry: drug interaction studies - study design, data analysis, implications for dosing and labeling recommendations. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/ucm292362.pdf. Accessed 26 Mar 2013.
17. van Giersbergen PL, Halabi A, Dingemanse J. Single- and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazole. Br J Clin Pharmacol. 2002;53(6):589-95.
18. Richards DB, Walker GA, Mandagere A, et al. Effect of ketoconazole on the pharmacokinetic profile of ambrisentan. J Clin Pharmacol. 2009;49(6):719-24.
19. Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet. 2000;38(2):111-80.
20. Julious SA, Debarnot CA. Why are pharmacokinetic data summarized by arithmetic means? J Biopharm Stat. 2000;10(1):55-71.
21. Sidharta PN, Dingemanse J. Multiple-dose tolerability, safety, pharmacokinetics, and pharmacodynamics of the dual endothelin receptor antagonist ACT-064992 in healthy human subjects (Abstract). J Clin Pharmacol. 2008;48:1114.
22. Honig PK, Wortham DC, Zamani K, et al. Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. JAMA. 1993;269(12):1513-8.
23. Dieterle W, Mann J. Pharmacokinetic interaction between ketoconazole and SPP301 in healthy volunteers. Int J Clin Pharmacol Ther. 2006;44(7):326-30.
24. Boxenbaum H. Cytochrome P450 3A4 in vivo ketoconazole competitive inhibition: determination of Ki and dangers associated with high clearance drugs in general. J Pharm Pharm Sci. 1999;2(2):47-52.
25. Chaikin P, Gillen MS, Malik M, et al. Co-administration of ketoconazole with H1-antagonists ebastine and loratadine in healthy subjects: pharmacokinetic and pharmacodynamic effects. Br J Clin Pharmacol. 2005;59(3):346-54.
26. Product Information: CLARITIN® tablets, syrup, and rapidly-disintegrating tablets. Kenilworth: Schering Corporation; 2000.
27. Abel S, Russell D, Taylor-Worth RJ, et al. Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. Br J Clin Pharmacol. 2008;65(Suppl 1):27-37.
28. Product Information: SELZENTRY® (maraviroc tablets). Research Triangle Park: ViiV Healthcare; 2012.
29. Grub S, Bryson H, Goggin T, et al. The interaction of saquinavir (soft gelatin capsule) with ketoconazole, erythromycin and rifampicin: comparison of the effect in healthy volunteers and in HIV-infected patients. Eur J Clin Pharmacol. 2001;57(2):115-21.
30. Product Information: INVIRASE® (saquinavir mesylate) capsules and tablets for oral use. South San Francisco: Genentech Inc.; 2012.
31. Jeong S, Nguyen PD, Desta Z. Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: major effect on CYPs 2B6, 2C9, 2C19, and 3A. Antimicrob Agents Chemother. 2009;53(2):541-51.